Cargando…

Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate

BACKGROUND: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Laner-Plamberger, Sandra, Lener, Thomas, Schmid, Doris, Streif, Doris A., Salzer, Tina, Öller, Michaela, Hauser-Kronberger, Cornelia, Fischer, Thorsten, Jacobs, Volker R., Schallmoser, Katharina, Gimona, Mario, Rohde, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641400/
https://www.ncbi.nlm.nih.gov/pubmed/26554451
http://dx.doi.org/10.1186/s12967-015-0717-4
_version_ 1782400197132812288
author Laner-Plamberger, Sandra
Lener, Thomas
Schmid, Doris
Streif, Doris A.
Salzer, Tina
Öller, Michaela
Hauser-Kronberger, Cornelia
Fischer, Thorsten
Jacobs, Volker R.
Schallmoser, Katharina
Gimona, Mario
Rohde, Eva
author_facet Laner-Plamberger, Sandra
Lener, Thomas
Schmid, Doris
Streif, Doris A.
Salzer, Tina
Öller, Michaela
Hauser-Kronberger, Cornelia
Fischer, Thorsten
Jacobs, Volker R.
Schallmoser, Katharina
Gimona, Mario
Rohde, Eva
author_sort Laner-Plamberger, Sandra
collection PubMed
description BACKGROUND: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We therefore searched for an efficient and reproducible medium preparation method that avoids clot formation while omitting animal-derived heparin. METHODS: We established a protocol to deplete fibrinogen by clotting of pHPL in medium, subsequent mechanical hydrogel disruption and removal of the fibrin pellet. After primary culture, bone-marrow and umbilical cord derived MSCs were tested for surface markers by flow cytometry and for trilineage differentiation capacity. Proliferation and clonogenicity were analyzed for three passages. RESULTS: The proposed clotting procedure reduced fibrinogen more than 1000-fold, while a volume recovery of 99.5 % was obtained. All MSC types were propagated in standard and fibrinogen-depleted medium. Flow cytometric phenotype profiles and adipogenic, osteogenic and chondrogenic differentiation potential in vitro were independent of MSC-source or medium type. Enhanced proliferation of MSCs was observed in the absence of fibrinogen but presence of heparin compared to standard medium. Interestingly, this proliferative response to heparin was not detected after an initial contact with fibrinogen during the isolation procedure. CONCLUSIONS: Here, we present an efficient, reproducible and economical method in compliance to good manufacturing practice for the preparation of MSC media avoiding xenogenic components and suitable for clinical studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0717-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4641400
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46414002015-11-12 Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate Laner-Plamberger, Sandra Lener, Thomas Schmid, Doris Streif, Doris A. Salzer, Tina Öller, Michaela Hauser-Kronberger, Cornelia Fischer, Thorsten Jacobs, Volker R. Schallmoser, Katharina Gimona, Mario Rohde, Eva J Transl Med Research BACKGROUND: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We therefore searched for an efficient and reproducible medium preparation method that avoids clot formation while omitting animal-derived heparin. METHODS: We established a protocol to deplete fibrinogen by clotting of pHPL in medium, subsequent mechanical hydrogel disruption and removal of the fibrin pellet. After primary culture, bone-marrow and umbilical cord derived MSCs were tested for surface markers by flow cytometry and for trilineage differentiation capacity. Proliferation and clonogenicity were analyzed for three passages. RESULTS: The proposed clotting procedure reduced fibrinogen more than 1000-fold, while a volume recovery of 99.5 % was obtained. All MSC types were propagated in standard and fibrinogen-depleted medium. Flow cytometric phenotype profiles and adipogenic, osteogenic and chondrogenic differentiation potential in vitro were independent of MSC-source or medium type. Enhanced proliferation of MSCs was observed in the absence of fibrinogen but presence of heparin compared to standard medium. Interestingly, this proliferative response to heparin was not detected after an initial contact with fibrinogen during the isolation procedure. CONCLUSIONS: Here, we present an efficient, reproducible and economical method in compliance to good manufacturing practice for the preparation of MSC media avoiding xenogenic components and suitable for clinical studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0717-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-10 /pmc/articles/PMC4641400/ /pubmed/26554451 http://dx.doi.org/10.1186/s12967-015-0717-4 Text en © Laner-Plamberger et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Laner-Plamberger, Sandra
Lener, Thomas
Schmid, Doris
Streif, Doris A.
Salzer, Tina
Öller, Michaela
Hauser-Kronberger, Cornelia
Fischer, Thorsten
Jacobs, Volker R.
Schallmoser, Katharina
Gimona, Mario
Rohde, Eva
Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
title Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
title_full Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
title_fullStr Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
title_full_unstemmed Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
title_short Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
title_sort mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641400/
https://www.ncbi.nlm.nih.gov/pubmed/26554451
http://dx.doi.org/10.1186/s12967-015-0717-4
work_keys_str_mv AT lanerplambergersandra mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT lenerthomas mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT schmiddoris mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT streifdorisa mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT salzertina mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT ollermichaela mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT hauserkronbergercornelia mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT fischerthorsten mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT jacobsvolkerr mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT schallmoserkatharina mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT gimonamario mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate
AT rohdeeva mechanicalfibrinogendepletionsupportsheparinfreemesenchymalstemcellpropagationinhumanplateletlysate